Clinical pharmacology of emicizumab for the treatment of hemophilia A
Expert Rev Clin Pharmacol. 2023 Aug 2. doi: 10.1080/17512433.2023.2243213. Online ahead of print.ABSTRACTINTRODUCTION: Emicizumab is a humanized bispecific antibody approved for the routine prophylaxis of bleeding episodes in patients with hemophilia A (PwHA) regardless of the presence of factor VIII (FVIII) inhibitors. It mimics the cofactor function of missing activated FVIII by bridging activated factor IX and factor X, thereby restoring hemostasis.AREAS COVERED: This review covers the clinical pharmacology of emicizumab and the translation of its pharmacokinetics (PK) and pharmacodynamics (PD) to clinical efficacy and ...
Source: Expert Review of Clinical Pharmacology - August 2, 2023 Category: Drugs & Pharmacology Authors: Koichiro Yoneyama Christophe Schmitt Agn ès Portron Anna Kiialainen Naoki Kotani Felix Jaminion Sylvie Retout Joanne I Adamkewicz Source Type: research

Short-acting versus long-acting opioids for pediatric postoperative pain management
Expert Rev Clin Pharmacol. 2023 Aug 7:1-11. doi: 10.1080/17512433.2023.2244417. Online ahead of print.ABSTRACTINTRODUCTION: Opioids are potent analgesics commonly used to manage children's moderate to severe perioperative pain in children. A wide range of short and long-acting opioids are used to treat surgical pain and will be reviewed in this article.AREAS COVERED: Both short- and long-acting opioids contain unique therapeutic benefits and adverse effects; however, due to the side effect profile and safety concerns, lack of familiarity, and evidence with long-acting opioids to treat surgical pain, shorter-acting opioids ...
Source: Expert Review of Clinical Pharmacology - August 2, 2023 Category: Drugs & Pharmacology Authors: Yun Han Chen Senthilkumar Sadhasivam Spencer DeMedal Mihaela Visoiu Source Type: research

Clinical pharmacology of emicizumab for the treatment of hemophilia A
Expert Rev Clin Pharmacol. 2023 Aug 2. doi: 10.1080/17512433.2023.2243213. Online ahead of print.ABSTRACTINTRODUCTION: Emicizumab is a humanized bispecific antibody approved for the routine prophylaxis of bleeding episodes in patients with hemophilia A (PwHA) regardless of the presence of factor VIII (FVIII) inhibitors. It mimics the cofactor function of missing activated FVIII by bridging activated factor IX and factor X, thereby restoring hemostasis.AREAS COVERED: This review covers the clinical pharmacology of emicizumab and the translation of its pharmacokinetics (PK) and pharmacodynamics (PD) to clinical efficacy and ...
Source: Expert Review of Clinical Pharmacology - August 2, 2023 Category: Drugs & Pharmacology Authors: Koichiro Yoneyama Christophe Schmitt Agn ès Portron Anna Kiialainen Naoki Kotani Felix Jaminion Sylvie Retout Joanne I Adamkewicz Source Type: research

Short-acting versus long-acting opioids for pediatric postoperative pain management
Expert Rev Clin Pharmacol. 2023 Aug 2. doi: 10.1080/17512433.2023.2244417. Online ahead of print.ABSTRACTINTRODUCTION: Opioids are potent analgesics commonly used to manage children's moderate to severe perioperative pain in children. A wide range of short and long-acting opioids are used to treat surgical pain and will be reviewed in this article.AREAS COVERED: Both short- and long-acting opioids contain unique therapeutic benefits and adverse effects; however, due to the side effect profile and safety concerns, lack of familiarity, and evidence with long-acting opioids to treat surgical pain, shorter-acting opioids have ...
Source: Expert Review of Clinical Pharmacology - August 2, 2023 Category: Drugs & Pharmacology Authors: Yun Han Chen Senthilkumar Sadhasivam Spencer DeMedal Mihaela Visoiu Source Type: research

Clinical pharmacology of emicizumab for the treatment of hemophilia A
Expert Rev Clin Pharmacol. 2023 Aug 2. doi: 10.1080/17512433.2023.2243213. Online ahead of print.ABSTRACTINTRODUCTION: Emicizumab is a humanized bispecific antibody approved for the routine prophylaxis of bleeding episodes in patients with hemophilia A (PwHA) regardless of the presence of factor VIII (FVIII) inhibitors. It mimics the cofactor function of missing activated FVIII by bridging activated factor IX and factor X, thereby restoring hemostasis.AREAS COVERED: This review covers the clinical pharmacology of emicizumab and the translation of its pharmacokinetics (PK) and pharmacodynamics (PD) to clinical efficacy and ...
Source: Expert Review of Clinical Pharmacology - August 2, 2023 Category: Drugs & Pharmacology Authors: Koichiro Yoneyama Christophe Schmitt Agn ès Portron Anna Kiialainen Naoki Kotani Felix Jaminion Sylvie Retout Joanne I Adamkewicz Source Type: research

Short-acting versus long-acting opioids for pediatric postoperative pain management
Expert Rev Clin Pharmacol. 2023 Aug 2. doi: 10.1080/17512433.2023.2244417. Online ahead of print.ABSTRACTINTRODUCTION: Opioids are potent analgesics commonly used to manage children's moderate to severe perioperative pain in children. A wide range of short and long-acting opioids are used to treat surgical pain and will be reviewed in this article.AREAS COVERED: Both short- and long-acting opioids contain unique therapeutic benefits and adverse effects; however, due to the side effect profile and safety concerns, lack of familiarity, and evidence with long-acting opioids to treat surgical pain, shorter-acting opioids have ...
Source: Expert Review of Clinical Pharmacology - August 2, 2023 Category: Drugs & Pharmacology Authors: Yun Han Chen Senthilkumar Sadhasivam Spencer DeMedal Mihaela Visoiu Source Type: research

Clinical pharmacology of emicizumab for the treatment of hemophilia A
Expert Rev Clin Pharmacol. 2023 Aug 2. doi: 10.1080/17512433.2023.2243213. Online ahead of print.ABSTRACTINTRODUCTION: Emicizumab is a humanized bispecific antibody approved for the routine prophylaxis of bleeding episodes in patients with hemophilia A (PwHA) regardless of the presence of factor VIII (FVIII) inhibitors. It mimics the cofactor function of missing activated FVIII by bridging activated factor IX and factor X, thereby restoring hemostasis.AREAS COVERED: This review covers the clinical pharmacology of emicizumab and the translation of its pharmacokinetics (PK) and pharmacodynamics (PD) to clinical efficacy and ...
Source: Expert Review of Clinical Pharmacology - August 2, 2023 Category: Drugs & Pharmacology Authors: Koichiro Yoneyama Christophe Schmitt Agn ès Portron Anna Kiialainen Naoki Kotani Felix Jaminion Sylvie Retout Joanne I Adamkewicz Source Type: research

Short-acting versus long-acting opioids for pediatric postoperative pain management
Expert Rev Clin Pharmacol. 2023 Aug 2. doi: 10.1080/17512433.2023.2244417. Online ahead of print.ABSTRACTINTRODUCTION: Opioids are potent analgesics commonly used to manage children's moderate to severe perioperative pain in children. A wide range of short and long-acting opioids are used to treat surgical pain and will be reviewed in this article.AREAS COVERED: Both short- and long-acting opioids contain unique therapeutic benefits and adverse effects; however, due to the side effect profile and safety concerns, lack of familiarity, and evidence with long-acting opioids to treat surgical pain, shorter-acting opioids have ...
Source: Expert Review of Clinical Pharmacology - August 2, 2023 Category: Drugs & Pharmacology Authors: Yun Han Chen Senthilkumar Sadhasivam Spencer DeMedal Mihaela Visoiu Source Type: research

Treatment and prevention of influenza in geriatric patients
Expert Rev Clin Pharmacol. 2023 Aug 1. doi: 10.1080/17512433.2023.2243221. Online ahead of print.ABSTRACTINTRODUCTION: Older adults are the most vulnerable population to the effects of influenza. These patients have age-related characteristics that make response to both infection and therapeutics different than younger patients.AREAS COVERED: Influenza vaccination and antiviral therapy are the foundational approach to preventing and treating influenza in geriatric patients. Older adults should receive one of three enhanced vaccines before influenza season beings. There are five antivirals used in influenza. Geriatric patie...
Source: Expert Review of Clinical Pharmacology - August 1, 2023 Category: Drugs & Pharmacology Authors: Marilyn N Bulloch Source Type: research

Clozapine for treatment refractory catatonia in individuals with autism spectrum disorder: a retrospective chart review study
CONCLUSIONS: Overall, clozapine was associated with a high response rate for the treatment of catatonia in patients with ASD. These naturalistic data support the use of clozapine for the treatment of catatonia in patients with ASD for whom lorazepam is either ineffective or partially effective.PMID:37526285 | DOI:10.1080/17512433.2023.2243820 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - August 1, 2023 Category: Drugs & Pharmacology Authors: Robyn P Thom Michael Wu Caitlin Ravichandran Christopher J McDougle Source Type: research

Treatment and prevention of influenza in geriatric patients
Expert Rev Clin Pharmacol. 2023 Aug 1. doi: 10.1080/17512433.2023.2243221. Online ahead of print.ABSTRACTINTRODUCTION: Older adults are the most vulnerable population to the effects of influenza. These patients have age-related characteristics that make response to both infection and therapeutics different than younger patients.AREAS COVERED: Influenza vaccination and antiviral therapy are the foundational approach to preventing and treating influenza in geriatric patients. Older adults should receive one of three enhanced vaccines before influenza season beings. There are five antivirals used in influenza. Geriatric patie...
Source: Expert Review of Clinical Pharmacology - August 1, 2023 Category: Drugs & Pharmacology Authors: Marilyn N Bulloch Source Type: research

Clozapine for treatment refractory catatonia in individuals with autism spectrum disorder: a retrospective chart review study
CONCLUSIONS: Overall, clozapine was associated with a high response rate for the treatment of catatonia in patients with ASD. These naturalistic data support the use of clozapine for the treatment of catatonia in patients with ASD for whom lorazepam is either ineffective or partially effective.PMID:37526285 | DOI:10.1080/17512433.2023.2243820 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - August 1, 2023 Category: Drugs & Pharmacology Authors: Robyn P Thom Michael Wu Caitlin Ravichandran Christopher J McDougle Source Type: research

Therapeutic drug monitoring: applying the 'Goldilocks Principle' to clinical pharmacology
Expert Rev Clin Pharmacol. 2023 Jul 26. doi: 10.1080/17512433.2023.2242161. Online ahead of print.NO ABSTRACTPMID:37496180 | DOI:10.1080/17512433.2023.2242161 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - July 27, 2023 Category: Drugs & Pharmacology Authors: Peter E Penson Alice P McCloskey Source Type: research